EXELIXIS, INC.

Nasdaq: EXEL·Alameda, California·

Price
$67.10
Base IV
$35.61

Valuation snapshot

Above base case

At $67.10, the price sits between our base case ($35.61) and bull case ($75.78).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$35.61
53% of the price · range $14.42–$75.78
Price vs base case
88% above
$67.10 against $35.61
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $14.42 to bull $75.78. Values per share.

Price against each value

Bear case
$14.42
Price 365% above
No growth
…
—
Base case
$35.61
Price 88% above
Researched bygemini-3.8-flash-medium
Valuation Oct 31, 2026 · Price as of Nov 16, 2026How we got here

What does Exelixis do?

Exelixis develops and markets pharmaceutical treatments, such as cabozantinib, to provide physicians with therapies for treating various types of cancer, including renal cell carcinoma and melanoma.

It brought in $2.5B of sales in the 12 months to Oct 2026.

Led by Michael M. Morrissey, Ph.D., President and Chief Executive Officer since 2010. Exelixis, Inc. Definitive Proxy Statement (Schedule 14A)

Industry
Healthcare
Based in
Alameda, California
Trades on
Nasdaq as EXEL

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Oct 2026, about 35¢ was left as profit after every cost, interest and tax. The biggest cost is research and development, 33¢ of every dollar.

  • Making what it sells4¢
  • Research and development33¢
  • Sales, marketing and admin23¢
  • Tax7¢
  • Left as profit35¢
  • Interest and other income came back in+3¢
Totals of the four quarters to Oct 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Exelixis, and for what?

Exelixis is an oncology biotechnology company that discovers, develops, and commercializes targeted cancer medicines. It makes money primarily by selling its flagship prescription cancer drugs, CABOMETYX and COMETRIQ, in the United States and by earning royalties and milestone payments from international pharmaceutical partners who market them abroad.

The company sells its prescription medicines primarily to wholesale pharmaceutical distributors and specialty pharmacies, with ultimate payment provided by government health programs and commercial insurers.

  • Net Product Revenues (CABOMETYX & COMETRIQ)

    92%

    Commercial sales of cabozantinib formulations in the United States for indications including kidney, liver, thyroid, and neuroendocrine cancers.

  • Cabozantinib Royalties

    8%

    Royalties earned on net sales of cabozantinib products outside the United States commercialized by collaboration partners Ipsen and Takeda.

  • License and Other Collaboration Revenues

    1%

    Milestone payments, research reimbursements, and license revenues earned from biopharmaceutical collaboration agreements.

Share of the latest fiscal year's sales, as the company reports it.

Exelixis, Inc. Form 10-K for the fiscal year ended January 2, 2026

How is the business doing?

Sales grew from $191.5M in 2016 to $2.3B in 2025, about 32% a year.

Running the business leaves about 40¢ of each sales dollar as operating profit, up from 15¢ in 2016.

After paying for its upkeep and new investment, it had $1.2B of cash to spare in the 12 months to Oct 2026.

Sales$2.3B
20122025
Operating margin38%
20122025
Free cash flow$875.8M
20122025
Each bar is one fiscal year (2012–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Exelixis exists to discover and deliver next-generation cancer therapies to help cancer patients recover and live longer.

“To help cancer patients recover stronger and live longer.”

Exelixis, Inc. Mission & Values

Who is responsible for the plan?

Roles checked November 14, 2026.

What management says it is working on now:

Total Revenues, Full Year 2026
$2.50 billion to $2.55 billion
Exelixis Reports Fourth Quarter and Full Year 2025 Financial Results
Net Product Revenues, Full Year 2026
$2.30 billion to $2.35 billion
Exelixis Reports Fourth Quarter and Full Year 2025 Financial Results
Cost of Goods Sold, Full Year 2026
Approximately 4% of net product revenues
Exelixis Reports Fourth Quarter and Full Year 2025 Financial Results
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 10% more than a year earlier. The year before, quarters averaged 9%.

Its operating margin is wider than a year ago: 41¢ per sales dollar, against 40¢.

Since Oct 2026 the share price has risen 1%, from $66.20 to $67.10.

Bull $75.78Base $35.61Bear $14.42Oct 30Nov 16 · $67.10
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Coming up

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Heavy Revenue Concentration in Cabozantinib

    The vast majority of revenue depends on commercial sales of CABOMETYX; any decline in market share, sales volume, or pricing would severely harm financial performance.

    From the company's own filingsWould hit how fast sales growExelixis, Inc. Form 10-K for the fiscal year ended January 2, 2026

  2. Generic Competition and Patent Litigation

    Multiple generic drugmakers have filed abbreviated new drug applications to market generic versions of CABOMETYX, which could sharply erode sales if patents are invalidated.

    From the company's own filingsWould hit its growth in the long runExelixis, Inc. Form 10-K for the fiscal year ended January 2, 2026

  3. Government Drug Pricing Reforms and the Inflation Reduction Act

    Government initiatives such as Medicare price negotiations, mandatory manufacturer inflation rebates, and international reference pricing may restrict drug prices and lower net realized revenue.

    From the company's own filingsWould hit how much of each sale it keepsExelixis, Inc. Form 10-K for the fiscal year ended January 2, 2026

  4. Payer Coverage, Reimbursement, and 340B Program Litigation

    If insurers restrict coverage or if ongoing legal disputes surrounding the 340B drug pricing program result in adverse rulings, revenue and profit margins could decrease.

    From the company's own filingsWould hit how much of each sale it keepsExelixis, Inc. Form 10-K for the fiscal year ended January 2, 2026

  5. Intense Oncology Market Competition

    Competitors with greater resources are developing novel targeted cancer therapies and combination regimens that may make Exelixis' therapies less preferred or obsolete.

    From the company's own filingsWould hit how fast sales growExelixis, Inc. Form 10-K for the fiscal year ended January 2, 2026

  6. Clinical Trial and Regulatory Approval Risks for Pipeline Assets

    Developing pipeline candidates like zanzalintinib is costly and uncertain; failure to achieve efficacy endpoints or gain regulatory approval could lead to substantial asset write-downs.

    From the company's own filingsWould hit how much it has to reinvestExelixis, Inc. Form 10-K for the fiscal year ended January 2, 2026

  7. Cabozantinib accounts for over 90% of total revenue, leaving the company vulnerable to severe patent cliff contraction if generic erosion outpaces pipeline commercialization.

    From our researchWould hit how fast sales growExelixis 2025 Form 10-K Segment Disclosures

  8. R&D expenditures may scale significantly as additional Phase 3 programs for antibody-drug conjugates enter the clinic.

    From our researchWould hit how much of each sale it keepsExelixis Q3 2026 Earnings Call Remarks

Is it a good business?

From 2012 to 2025 it earned between -1,688% and 36% on its shareholders' equity, a median of 8%.

Over 10 years its operating margin ranged from $8.94 to 38¢ per sales dollar, a median of 3¢. Gross margin ran from 67¢ to 96¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on equity36%
20122025
Return on invested capital is operating profit after tax (at the median effective rate, —) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 8.2% in a year, so each remaining share owns a slightly bigger slice.

What might it be worth?

Net debt is excluded: The last balance sheet with both cash and debt is too old for this valuation. The per-share value may change when resolved. Last published debt: $0 as of 2017-06-30.

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $67.10. Our put its value between $14.42 and $75.78, with $35.61 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $14.42

This scenario envisions sales growth stalling and turning steeply negative as low-cost generic competitors enter in 2030, while pipeline drugs fail to make up for lost earnings.

Base case, $35.61

This scenario assumes recent ten percent sales growth moderates before manageable generic competition arrives in 2030, with newer cancer medicines cushioning the decline and sustaining solid cash generation.

Bull case, $75.78

This scenario models double-digit sales growth driven by successful launches of next-generation cancer therapies, keeping overall revenue climbing even as generic competition enters in 2030.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 88%

For Exelixis to be worth today's $67.10, sales would need to grow about 14.2% a year. We assume they shrink 1.0%. Over the last 5 years, sales grew 18.2% a year.

−5%0%+5%+10%+15%+20%+25%We assume −1.0%Price needs 14.2%Past 5 yrs 18.2%

Or, if sales shrink 1.0% as we assume, the price works with a profit margin of 66.0% (we assume 35.0%).

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 14.2% a year?

Try your own numbers

We're not very sure of this range: it scores 49 out of 100 on our checks. The weakest point is historical stability.

Test the assumptions

Our base value of $35.61 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average-1.0%
  • Operating margin35.0%
  • Long-term growth rate1.8%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$35.61 -46.9%

Build